½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 3 April 2020 ¨C 20:00 (CEST) ¨C regulated information

Acquisitions of own shares
In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀÖ³Ç SA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2020. 

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 1.2 million ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of an initial discretionary mandate agreement with validity until 15 June 2020, effective as from 25 March 2020, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2020, ½ðºÌÓéÀÖ³Ç repurchased 270 650 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 25 March 2020 up to and including 2 April 2020, as follows: 

Disposals of own shares
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, ½ðºÌÓéÀÖ³Ç announces that, following exercises of stock options by members of its personnel, it has disposed of ½ðºÌÓéÀÖ³Ç shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group, as follows:

 
In addition to these exercises, on 1 April 2020, in accordance with the vesting rules under its 2017 LTI plans, ½ðºÌÓéÀÖ³Ç SA/NV has delivered for free a total of 379 913 ½ðºÌÓéÀÖ³Ç shares OTC to 1 288 members of the personnel of the Company and its subsidiaries.
The highest independent bid price on Euronext Brussels on 1 April 2020 was € 81.20.

On 2 April 2020, taking into account the acquisitions of own shares mentioned in the first section and after settlement of the deliveries of shares to members of the personnel mentioned in this section, ½ðºÌÓéÀÖ³Ç SA/NV (taking into account the holdings of its affiliates) owned 5 558 893 ½ðºÌÓéÀÖ³Ç shares, which represent 2.86% of the total number of shares issued by the company (194 505 658).

An updated overview of the ½ðºÌÓéÀÖ³Ç SA/NV large shareholdings is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following .

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

Investor Relations
Antje Witte, Investor Relations, ½ðºÌÓéÀÖ³Ç
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck, Investor Relations, ½ðºÌÓéÀÖ³Ç
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news